First Time Loading...

Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211

Watchlist Manager
Tibet Rhodiola Pharmaceutical Holding Co Logo
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Watchlist
Price: 38.7 CNY -0.9%
Updated: May 14, 2024

Tibet Rhodiola Pharmaceutical Holding Co
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Tibet Rhodiola Pharmaceutical Holding Co
Gross Profit Peer Comparison

Comparables:
1099
601607
600998
C
600511
000963

Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Gross Profit
¥3B
CAGR 3-Years
36%
CAGR 5-Years
29%
CAGR 10-Years
27%
Sinopharm Group Co Ltd
HKEX:1099
Gross Profit
¥49B
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
15%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Gross Profit
¥31B
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
12%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Gross Profit
¥11.4B
CAGR 3-Years
4%
CAGR 5-Years
9%
CAGR 10-Years
17%
C
China National Medicines Corp Ltd
SSE:600511
Gross Profit
¥4B
CAGR 3-Years
8%
CAGR 5-Years
3%
CAGR 10-Years
18%
Huadong Medicine Co Ltd
SZSE:000963
Gross Profit
¥12.6B
CAGR 3-Years
4%
CAGR 5-Years
9%
CAGR 10-Years
15%

See Also

What is Tibet Rhodiola Pharmaceutical Holding Co's Gross Profit?
Gross Profit
3B CNY

Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Gross Profit amounts to 3B CNY.

What is Tibet Rhodiola Pharmaceutical Holding Co's Gross Profit growth rate?
Gross Profit CAGR 10Y
27%

Over the last year, the Gross Profit growth was 27%. The average annual Gross Profit growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 36% over the past three years , 29% over the past five years , and 27% over the past ten years .